Andi Qipo, MD
Hospitalist · Fair Lawn, NJNPI 1164768461
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 79 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by Novo Nordisk at 30.7% of the total. Among hospitalist clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 79 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$469
- Boehringer Ingelheim$206
- Exact Sciences$150
- Astellas Pharma US Inc$134
- Pfizer$80
- GSK$71
- plus $418 from 14 others
What the payments were for
- Food & beverage$1,528100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $469 |
| Boehringer Ingelheim | 12 | $206 |
| Exact Sciences | 7 | $150 |
| Astellas Pharma US Inc | 6 | $134 |
| Pfizer | 5 | $80 |
| GSK | 4 | $71 |
| Lilly USA, LLC | 4 | $70 |
| Medtronic | 2 | $64 |
| Teva Pharmaceuticals USA, Inc. | 3 | $51 |
| AstraZeneca | 3 | $47 |
| Inspire Medical Systems, Inc. | 1 | $27 |
| Abbott | 1 | $24 |
| Alvogen Inc | 1 | $20 |
| Renalytix AI, Inc. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $18 |
| Ardelyx, Inc. | 1 | $18 |
| Amgen | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
| AbbVie | 1 | $13 |
How this compares
$1,528 in reported general payments places this provider in the 90th percentile of 567 hospitalist providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 26 | $165,991 |
| JardianceEmpagliflozin | 122 | $99,635 |
| XifaxanRifaximin | 46 | $93,022 |
| EliquisApixaban | 128 | $90,543 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 16 | $67,263 |
| JanuviaSitagliptin Phosphate | 49 | $49,854 |
| LinzessLinaclotide | 51 | $44,569 |
| OzempicSemaglutide | 38 | $41,070 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 20 | $37,117 |
| XareltoRivaroxaban | 46 | $35,854 |
| JanumetSitagliptin Phos/Metformin Hcl | 38 | $34,796 |
| TivicayDolutegravir Sodium | 15 | $30,585 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $24,775 |
| Dihydroergotamine Mesylate | 11 | $24,146 |
| TradjentaLinagliptin | 28 | $19,361 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $51 | $165,99126 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $206 | $126,365164 claims |
| PfizerEliquis | $80 | $90,543128 claims |
| AbbVieLinzess, Namzaric, Lumigan | $13 | $55,52476 claims |
| Novo NordiskOzempic | $469 | $41,07038 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $71 | $39,66170 claims |
| AstraZenecaBrilinta | $47 | $11,62117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 567 hospitalist providers in New Jersey.
Other hospitalist in Fair Lawn
- Mohammed UsmanToms River$33K
- Justin BaptistAtlantic City$23K
- Jhonsua Jimenez AriasMorristown$15K
- Ahmed HassaninMorristown$15K
- Mohamed BakrAtlantic City$8K
- Jason NehmadNeptune$7K
- Rebecca ZweiflerMorristown$6K
- Scott KaufmanMount Holly$6K
- Kunal ParmarPompton Plains$6K
- Sameh GirgisNeptune$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.